Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer.

Law, AMK; Valdes-Mora, F; Gallego-Ortega, D

Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer.

Law, AMK Valdes-Mora, F Gallego-Ortega, D

Permalink

Publisher:: MDPI
Publication Type:: Journal Article
Citation:: Cells, 2020, 9, (3)
Issue Date:: 2020-02-27

Recently Added

	Filename	Description	Size
	Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer.pdf	Published Version	3.77 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is new to OPUS and is not currently available.

Full metadata record

Field	Value	Language
dc.contributor.author	Law, AMK
dc.contributor.author	Valdes-Mora, F
dc.contributor.author	Gallego-Ortega, D
dc.date.accessioned	2021-01-08T02:06:58Z
dc.date.available	2020-02-24
dc.date.available	2021-01-08T02:06:58Z
dc.date.issued	2020-02-27
dc.identifier.citation	Cells, 2020, 9, (3)
dc.identifier.issn	2073-4409
dc.identifier.issn	2073-4409
dc.identifier.uri	http://hdl.handle.net/10453/145209
dc.description.abstract	The emergence of immunotherapy has been an astounding breakthrough in cancer treatments. In particular, immune checkpoint inhibitors, targeting PD-1 and CTLA-4, have shown remarkable therapeutic outcomes. However, response rates from immunotherapy have been reported to be varied, with some having pronounced success and others with minimal to no clinical benefit. An important aspect associated with this discrepancy in patient response is the immune-suppressive effects elicited by the tumour microenvironment (TME). Immune suppression plays a pivotal role in regulating cancer progression, metastasis, and reducing immunotherapy success. Most notably, myeloid-derived suppressor cells (MDSC), a heterogeneous population of immature myeloid cells, have potent mechanisms to inhibit T-cell and NK-cell activity to promote tumour growth, development of the pre-metastatic niche, and contribute to resistance to immunotherapy. Accumulating research indicates that MDSC can be a therapeutic target to alleviate their pro-tumourigenic functions and immunosuppressive activities to bolster the efficacy of checkpoint inhibitors. In this review, we provide an overview of the general immunotherapeutic approaches and discuss the characterisation, expansion, and activities of MDSCs with the current treatments used to target them either as a single therapeutic target or synergistically in combination with immunotherapy.
dc.format	Electronic
dc.language	eng
dc.publisher	MDPI
dc.relation.ispartof	Cells
dc.relation.isbasedon	10.3390/cells9030561
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.title	Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer.
dc.type	Journal Article
utslib.citation.volume	9
utslib.location.activity	Switzerland
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Mathematical and Physical Sciences
pubs.organisational-group	/University of Technology Sydney
utslib.copyright.status	recently_added	*
pubs.consider-herdc	false
dc.date.updated	2021-01-08T02:06:37Z
pubs.issue	3
pubs.publication-status	Published
pubs.volume	9
utslib.citation.issue	3

Abstract:

The emergence of immunotherapy has been an astounding breakthrough in cancer treatments. In particular, immune checkpoint inhibitors, targeting PD-1 and CTLA-4, have shown remarkable therapeutic outcomes. However, response rates from immunotherapy have been reported to be varied, with some having pronounced success and others with minimal to no clinical benefit. An important aspect associated with this discrepancy in patient response is the immune-suppressive effects elicited by the tumour microenvironment (TME). Immune suppression plays a pivotal role in regulating cancer progression, metastasis, and reducing immunotherapy success. Most notably, myeloid-derived suppressor cells (MDSC), a heterogeneous population of immature myeloid cells, have potent mechanisms to inhibit T-cell and NK-cell activity to promote tumour growth, development of the pre-metastatic niche, and contribute to resistance to immunotherapy. Accumulating research indicates that MDSC can be a therapeutic target to alleviate their pro-tumourigenic functions and immunosuppressive activities to bolster the efficacy of checkpoint inhibitors. In this review, we provide an overview of the general immunotherapeutic approaches and discuss the characterisation, expansion, and activities of MDSCs with the current treatments used to target them either as a single therapeutic target or synergistically in combination with immunotherapy.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/145209